BLOOMBERG BUSINESSWEEK: A US company will next month report the results of its study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer, also called castration-resistant prostate cancer. READ MORE>
Posts Tagged ‘abiraterone acetate’
Abiraterone acetate: A promising drug for the treatment of castration-resistant prostate cancer
Posted in Chemotherapy, Hormone therapy, Hormone-refactory, PROSTATE CANCER, Prostate drugs, PROSTATE RESEARCH, tagged abiraterone acetate, advanced prostate cancer, cancer research, castration, castration-resistant disease, catheter, Chemotherapy, Hormone therapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment debate, URO TODAY on May 29, 2010| 1 Comment »
URO TODAY: Abiraterone acetate is a promising treatment for advanced prostate cancer patients and is being tested in a Phase III trial for men with progressive castration-resistant prostate cancer who have not had chemotherapy.
A Phase III trial for patients following prior chemotherapy has been completed and is awaiting analysis. READ MORE>
Promising drugs being developed to prevent eventual failure of hormone therapy for prostate cancer
Posted in Hormone therapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged abiraterone acetate, adrenal gland, advanced prostate cancer, androgen receptor, cancer research, CYP17A inhibitor, early phase trials, Hormone therapy, MDV3100, new anti-androgen, over-expressed androgen receptor, phase three testing, prostablog, prostate, prostate blog, prostate cancer growth, prostate cancer treatments, prostate treatment, prostate treatment debate, steroid biosynthesis, URO TODAY on October 30, 2009| Leave a Comment »
URO TODAY: Activation of the androgen receptor is crucial for prostate cancer growth at all points of the illness, and two new drugs are showing promise in preventing that happen. READ MORE>
Notably, promising activity has been shown in early phase trials by MDV3100, a new anti-androgen designed for activity in prostate cancer model systems with over-expressed androgen receptor, and by abiraterone acetate, a CYP17A inhibitor that blocks steroid biosynthesis in the adrenal gland and possibly within the tumour. Both agents are undergoing phase three testing.
Johnson and Johnson buys bio-tech co. conducting trials of steroid anti-androgen prostate drug
Posted in New prostate drugs, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged abiraterone acetate, Associated Press, cancer research, Cougar Biotechnology Inc, Johnson & Johnson, late stage clinical trials, potential vaccine for prostate cance, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment on July 12, 2009| Leave a Comment »
JULY 12: ASSOCIATED PRESS: Johnson & Johnson says it has completed its $US893.7 million acquisition of Cougar Biotechnology Inc, a development stage company that is testing a potential vaccine for prostate cancer. Los Angeles-based Cougar is conducting two late stage clinical trials of abiraterone acetate as a treatment for prostate cancer. READ MORE>
PROSTATE TREATMENT: Drug leads to big PSA drop in castrate-reisistant patients
Posted in Hormone-refactory, New prostate drugs, PROSTATE CANCER, PROSTATE RESEARCH, PSA tests, tagged abiraterone acetate, advanced prostate cancer, cancer research, castration-resistant prostate cancer, Hormone therapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, prostate-specific antigen, PSA, PSA test, REUTERS HEALTH on June 19, 2009| 1 Comment »
PROSTATE RESEARCH: New data on success of post-hormonal treatment drug
Posted in Biochemical recurrence, Hormone therapy, New prostate drugs, PROSTATE CANCER, Prostate drugs, PROSTATE RESEARCH, Treatment news, tagged abiraterone acetate, advanced prostate cancer, cancer research, ketoconazole, ketoconazole-naive patients, Mike Scott, New Prostate Cancer Info-link, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, US oncologists conference on June 1, 2009| Leave a Comment »
JUNE 1: NEW PROSTATE CANCER INFO-LINK: Abiraterone acetate does in fact work in patients who have been previously treated with ketoconazole — but it definitely doesn’t seem to work as well in these patients as it does in the ketoconazole-naive patients, writes Mike Scott from the US oncologists conference. READ MORE> on this and other papers.
PROSTATE DRUG: Pill stops tumour cells from making hormone they need to survive
Posted in PROSTATE CANCER, Prostate claims, Prostate drugs, tagged abiraterone acetate, cancer research, Cougar Biotechnology, experimental drug, Johnson & Johnson, Journal of Clinical Oncology, NEW JERSEY BUSINESS NEWS, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate on May 28, 2009| Leave a Comment »
MAY 28: NEW JERSEY BUSINESS NEWS: Cougar Biotechnology, the developer of cancer medicines that Johnson & Johnson agreed to buy last week, said its lead experimental drug worked against prostate tumours in a company-sponsored study. READ MORE>
